Time course of LDL-C lowering after initiation of PCSK9 inhibition or bempedoic acid in atherosclerotic cardiovascular disease

20 March 2026 (08:00 - 18:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Edita Pogran

Ottakring Clinic, Vienna (Austria)

71 More presentations in this session

Presentation thumbnail

Multimodality imaging of the aortic root and ascending aorta: a comparative study of CTA and echocardiography

Mr G. Imperatore (Pisa, IT)

Abstract Slides

Presentation thumbnail

Impact of atrial fibrillation burden on heart failure device alerts and therapy delivery: insights from remote monitoring in an island-based heart failure cohor

Doctor I. Almeida (Ponta Delgada, PT)

Abstract Slides

Presentation thumbnail

Respiratory infections as triggers of acute cardiovascular complications: a case series of new-onset atrial fibrillation and heart failure

Doctor A. Akhtar (Waterford, IE)

Abstract Slides

Presentation thumbnail

Stabilizing the unstable: characterization of advanced heart failure patients under intermittent levosimendan therapy

Doctor R. Brandao (Amadora, PT)

Abstract Slides

Presentation thumbnail

Predictors of Levosimendan reinitiation in patients with advanced heart failure undergoing intermittent inotropic therapy- is the lung that important?

Doctor R. Brandao (Amadora, PT)

Abstract Slides

Access the full session

Session thumbnail

Poster session (1)

The Event

Event poster

ESC Acute CardioVascular Care 2026

20 March - 21 March 2026

You may be interested in

Congress Presentation

Lipid control in cardiovascular patients

Congress Presentation

What’s new in LDL lowering?

Congress Presentation

Stepwise approach to lipid-lowering therapies: which one, when, and for whom?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources